Histone deacetylase‐2: A potential regulator and therapeutic target in liver disease (Review)

Ya-Ru Liu,Jie-Quan Wang,Zhao-Gang Huang,Ruo-Nan Chen,Xi Cao,Dong-Chun Zhu,Hai-Xia Yu,Xiu-Rong Wang,Hai-Yun Zhou,Quan Xia,Jun Li
DOI: https://doi.org/10.3892/ijmm.2021.4964
IF: 5.314
2021-05-18
International Journal of Molecular Medicine
Abstract:Histone acetyltransferases are responsible for histone acetylation, while histone deacetylases (HDACs) counteract histone acetylation. An unbalanced dynamic between histone acetylation and deacetylation may lead to aberrant chromatin landscape and chromosomal function. HDAC2, a member of class I HDAC family, serves a crucial role in the modulation of cell signaling, immune response and gene expression. HDAC2 has emerged as a promising therapeutic target for liver disease by regulating gene transcription, chromatin remodeling, signal transduction and nuclear reprogramming, thus receiving attention from researchers and clinicians. The present review introduces biological information of HDAC2 and its physiological and biochemical functions. Secondly, the functional roles of HDAC2 in liver disease are discussed in terms of hepatocyte apoptosis and proliferation, liver regeneration, hepatocellular carcinoma, liver fibrosis and non‑alcoholic steatohepatitis. Moreover, abnormal expression of HDAC2 may be involved in the pathogenesis of liver disease, and its expression levels and pharmacological activity may represent potential biomarkers of liver disease. Finally, research on selective HDAC2 inhibitors and non‑coding RNAs relevant to HDAC2 expression in liver disease is also reviewed. The aim of the present review was to improve understanding of the multifunctional role and potential regulatory mechanism of HDAC2 in liver disease.
medicine, research & experimental
What problem does this paper attempt to address?